Oncoinvent Sets Regulatory Strategy for Development of Radspherin ®

Oncoinvent Sets Regulatory Strategy for Development of Radspherin ®

PR Newswire

STOCKHOLM, April 13, 2018

STOCKHOLM, April 13, 2018 /PRNewswire/ --

Oncoinvent announced today that the regulatory strategy that will be used in the development of its lead product Radspherin® has been selected.

The company has previously communicated that there are two equally attractive commercialization options available for Radspherin®.  Due to Radspherin®'s inherent product characteristics the company has the option of either developing Radspherin as a medical device, or as a medicinal product.  In the past, development of medical devices in Europe has traditionally taken significantly less time and has cost less than the development of medicinal products, an advantage that Oncoinvent has been considering could potentially lead to a faster time to market in Europe for Radspherin®.

Changes to the regulatory requirements for European market access

Requirements for medical devices are changing in the EU.

The new Medical Devices Regulation and IVD Regulation that was published in 2017 will have a dramatic effect on the future medical device industry. One consequence of the new regulation is that clinical data requirements and clinical development times and costs for medical devices will become significantly longer and greater respectively by the year 2020.

Based on input from the FDA, the Norwegian Medicines Agency, the German Notified Body TÜV-SÜD, in addition to expert advice received in the areas of clinical development, regulatory approvals, and market access, the company has now made the decision to develop Radspherin® as a medicinal product.

Oncoinvent CEO Jan A. Alfheim commented," After thoroughly analyzing the potential risks and benefits of the two regulatory pathways for Radspherin® we have concluded that selecting a medicinal product regulatory strategy for the USA and Europe will have a limited impact on the necessary future development cost, while providing a greater market potential for Radspherin®.  This decision will affect the start of our planned phase I clinical trials, which we now plan to start early next year.  We have concluded that the company's decision best serves the interests of the company and our shareholders in the long term"


For further information, please contact:

Jan A. Alfheim, Chief Executive Officer
Cell: +47-46-44-00-45
Email: alfheim@oncoinvent.com

IR enquiries:

Ole Peter Nordby, Chief Financial Officer 

Cell: +47-41-28-71-79 

Email: nordby@oncoinvent.com

This information was brought to you by Cision http://news.cision.com


Voltar noticias em Inglês